Not Signed In -
Irbesartan |
Avapro |
Irbesartan Systematic (IUPAC) name 2-butyl- 3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]- 1,3-diazaspiro[4.4]non-1-en-4-one Identifiers CAS number 138402-11-6 ATC code C09CA04 PubChem 3749 DrugBank APRD00413 Chemical data Formula C25H28N6O Mol. weight 428.53 Pharmacokinetic data Bioavailability 60–80% Metabolism Hepatic (CYP2C9) Half life 11–15 hours Excretion Renal 20%, faecal 65% Therapeutic considerations Pregnancy cat. D (Au) Legal status S4 (A ...
Wikipedia - [full article]
Irbesartan Clinical Trials
- Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve)
ClinicalTrials.gov Identifier: NCT00095238 - Active, not recruiting
Congestive Heart Failure
- Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
ClinicalTrials.gov Identifier: NCT00265642 - Recruiting
Hepatitis C, Chronic
- I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients
ClinicalTrials.gov Identifier: NCT00335673 - Active, not recruiting
Hypertension
- Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients with Hypertension and Permanent Pacemakers
ClinicalTrials.gov Identifier: NCT00225667 - Not yet recruiting
Atrial Fibrillation; Hypertension
- Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
ClinicalTrials.gov Identifier: NCT00334581 - Recruiting
Hypertension
- I PREVENT - Irbesartan In Hypertensive Diabetic Patients
ClinicalTrials.gov Identifier: NCT00362258 - Recruiting
Hypertension
- Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients with Hypercholesterolemia
ClinicalTrials.gov Identifier: NCT00152698 - Completed
Hypercholesterolemia
- Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension
ClinicalTrials.gov Identifier: NCT00263003 - Completed
Hypertension
- I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy
ClinicalTrials.gov Identifier: NCT00362037 - Recruiting
Hypertension
- Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing
ClinicalTrials.gov Identifier: NCT00443612 - Recruiting
Hypertension
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE)
ClinicalTrials.gov Identifier: NCT00249795 - Active, not recruiting
Atrial Fibrillation; Cardiovascular Disease
- Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
ClinicalTrials.gov Identifier: NCT00343551 - Active, not recruiting
Essential Hypertension
- Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
ClinicalTrials.gov Identifier: NCT00095394 - Completed
Hypertension
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE)
ClinicalTrials.gov Identifier: NCT00249873 - Active, not recruiting
Atrial Fibrillation; Vascular Risk
- Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients with Moderate Hypertension
ClinicalTrials.gov Identifier: NCT00095550 - Completed
Hypertension
- Irbesartan in Hypertension
ClinicalTrials.gov Identifier: NCT00265967 - Active, not recruiting
Hypertension
- Irbesartan vs. Placebo in Combination with Ramipril for Treatment of Albuminuria
ClinicalTrials.gov Identifier: NCT00095290 - Completed
Albuminuria
- Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
ClinicalTrials.gov Identifier: NCT00500604 - Recruiting
Hypertension
- Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
ClinicalTrials.gov Identifier: NCT00517322 - Recruiting
Left Atrial Volume; Hypertensive Heart Disease; Antihypertensive Drugs; Diastolic Function; Renin Angiotensin System
- Irbesartan in the Treatment of Hypertensive Patients with Metabolic Syndrome
ClinicalTrials.gov Identifier: NCT00110422 - Completed
Metabolic Syndrome X; Hypertension
- Comparison of Vascular Effects After Therapy with Irbesartan and Atorvastatin.
ClinicalTrials.gov Identifier: NCT00154024 - Completed
Healthy subjects
- Left Ventricular Function After AMI. Treatment with Angiotensin 2-Receptor Blockade (GLOBAL-Study)
ClinicalTrials.gov Identifier: NCT00125645 - Recruiting
Acute myocardial infarction (AMI)
- Irbesartan and Atenolol in Hypertensive Heart Disease
ClinicalTrials.gov Identifier: NCT00389168 - Completed
Hypertension
- Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
ClinicalTrials.gov Identifier: NCT00350038 - Completed
Hypertension; Dyslipidemia
- ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
ClinicalTrials.gov Identifier: NCT00296218 - Completed
Myocardial Ischemia; Hypertension
- Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
ClinicalTrials.gov Identifier: NCT00564187 - Completed
Hypertension
- The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
ClinicalTrials.gov Identifier: NCT00185055 - Completed
Healthy
- Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
ClinicalTrials.gov Identifier: NCT00529750 - Completed
Hypertension
- Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol
ClinicalTrials.gov Identifier: NCT00549133 - Completed
Hypertension; Diabetes Mellitus Type 2
- VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-Term Hemodialysis
ClinicalTrials.gov Identifier: NCT00171080 - Completed
Hypertension
- The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
ClinicalTrials.gov Identifier: NCT00562809 - Completed
Hypertension
- Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
ClinicalTrials.gov Identifier: NCT00320879 - Completed
Type 2 Diabetes; Microalbuminuria
- Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
ClinicalTrials.gov Identifier: NCT00464880 - Completed
Diabetes Type 2
- APROVE : Irbesartan in Hypertension
ClinicalTrials.gov Identifier: NCT00283036 - Completed
Hypertension
- Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
ClinicalTrials.gov Identifier: NCT00352560 - Completed
Atrial Fibrillation
- A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
ClinicalTrials.gov Identifier: NCT00219115 - Completed
Hypertension
- Irbesartan in Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00317915 - Completed
Type 2 Diabetes; Microalbuminuria; Hypertension
- Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure
ClinicalTrials.gov Identifier: NCT00347087 - Completed
Chronic Heart Failure
- Prevention of Kidney Transplant Rejection
ClinicalTrials.gov Identifier: NCT00005010 - Completed
End-Stage Renal Disease; Chronic Allograft Nephropathy
- Using the Drug Spironolactone to test if it Reduces Protein Leakage from the Kidney
ClinicalTrials.gov Identifier: NCT00106561 - Completed
Kidney Disease; Diabetic Nephropathy; Glomerulonephritis; Proteinuria
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE)
ClinicalTrials.gov Identifier: NCT00243178 - Terminated
Atrial Fibrillation; Vascular Risk
Resources
- Avapro (Drug Digest)
- Irbesartan (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
